Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Pharmacopsychiatry ; 46(1): 10-5, 2013 Jan.
Article in English | MEDLINE | ID: mdl-22592505

ABSTRACT

INTRODUCTION: Here, we present a stem-cell based study on the de-novo generation of beta-III-tubulin-positive neurons after treatment with the classic antipsychotic drug haloperidol or after treatment with the second-generation antipsychotic (SGA) ziprasidone. METHODS: Adult neural stem cells (ANSC) dissociated from the adult mouse hippocampus were expanded in cell culture with basic fibroblast growth factor (bFGF) and epidermal growth factor (EGF). ANSC differentiated upon withdrawal of EGF and bFGF. RESULTS AND DISCUSSION: Ziprasidone generated significantly more beta-III-tubulin-positive neurons than haloperidol during the differentiation of adult neural stem cells isolated from murine hippocampus (ANSC). We assume that this net increase in neurogenesis by ziprasidone relies on this drug's 5-HT1A receptor affinity, which is not present in the haloperidol molecule, since the inactivation by WAY100621 impeded this process. These data could possibly suggest a clinical relevance for studying antipsychotic drugs in the stem cell paradigm employed in this study.


Subject(s)
Antipsychotic Agents/pharmacology , Haloperidol/pharmacology , Hippocampus/cytology , Neural Stem Cells/drug effects , Neurogenesis/drug effects , Piperazines/pharmacology , Thiazoles/pharmacology , Animals , Cell Differentiation/drug effects , Cell Movement/drug effects , Cells, Cultured , Epidermal Growth Factor/pharmacology , Fibroblast Growth Factor 2/pharmacology , Hippocampus/drug effects , Immunohistochemistry , Mice , Mice, Inbred C57BL , Receptor, Serotonin, 5-HT1A/drug effects , Serotonin Antagonists/pharmacology , Tubulin/biosynthesis
2.
Pharmacopsychiatry ; 45 Suppl 1: S36-41, 2012 May.
Article in English | MEDLINE | ID: mdl-22565233

ABSTRACT

Schizophrenia is a complex dynamic disorder comprising a wide range of neurobiological alterations including dopaminergic dysfunction. The aim of the study was to investigate dynamic changes of dopaminergic neurotransmission in patients with schizophrenia (n=8, mean age 25.4 ± 5.8 years) in early stages of the disorder, compared to healthy control subjects (n=7, mean age 23.6 ± 2.7 years). A dynamic IBZM SPECT protocol was used to assess the endogenous dopamine release following an amphetamine challenge. Subjects received a bolus activity of 175 MBq followed by a continuous infusion of 45 MBq/h [123I]IBZM. SPECT scans were performed 2 h after bolus injection, and 1 h following the amphetamine challenge (0.3 mg/kg). Striatal IBZM binding to dopamine D2 receptors was assessed with a volume-of-interest (VOI) technique. The change in IBZM binding between pre- and post-challenge scans was used as a measure of endogenous dopamine release triggered by amphetamine. At baseline, patients showed higher mean striatal IBZM binding compared to controls (0.77 ± 0.09 vs. 0.68 ± 0.07, p=0.07). There was a statistically significant difference in IBZM binding between patients, with a predominance of negative vs. positive symptoms (0.84 ± 0.08 vs. 0.71 ± 0.04, p<0.05). Upon amphetamine challenge, mean IBZM binding decreased by about 4.9 ± 7.6% in controls (n=7) compared to a mean of 12.4 ± 5.8% in subjects with schizophrenia (p<0.05). In patients, paranoid symptoms showed a significant negative correlation with IBZM baseline binding, whereas there was a trend towards positive correlation with the decrease of IBZM binding under challenge. Negative symptoms showed positive associations with baseline IBZM binding. The data are in line with previous reports and contribute to the notion of a dynamic instability of the dopaminergic system in patients with schizophrenia, taking into account the psychopathology with respect to positive or negative symptoms.


Subject(s)
Dopamine/physiology , Schizophrenia/physiopathology , Schizophrenic Psychology , Synaptic Transmission/physiology , Adolescent , Adult , Benzamides , Central Nervous System Stimulants , Dextroamphetamine , Diagnostic and Statistical Manual of Mental Disorders , Dopamine/metabolism , Female , Humans , Image Processing, Computer-Assisted , Male , Pyrrolidines , Receptors, Dopamine D2/metabolism , Receptors, Presynaptic/metabolism , Schizophrenia/diagnostic imaging , Tomography, Emission-Computed, Single-Photon , Young Adult
3.
Neurology ; 77(15): 1453-6, 2011 Oct 11.
Article in English | MEDLINE | ID: mdl-21987641

ABSTRACT

OBJECTIVE: We investigated whether crossed legs are a prognostic marker in patients with severe stroke. METHODS: In this controlled prospective observational study, we observed patients with severe stroke who crossed their legs during their hospital stay and matched them with randomly selected severe stroke patients who did not cross their legs. The patients were evaluated upon admission, on the day of leg crossing, upon discharge, and at 1 year after discharge. The Glasgow Coma Scale, the NIH Stroke Scale (NIHSS), the modified Rankin Scale (mRS), and the Barthel Index (BI) were obtained. RESULTS: Patients who crossed their legs (n = 34) and matched controls (n = 34) did not differ in any scale upon admission. At the time of discharge, the GCS did not differ, but the NIHSS was better in crossed legs patients (6.5 vs 10.6; p = 0.0026), as was the mRS (3.4 vs 5.1, p < 0.001), and the BI (34.0 vs 21.1; p = 0.0073). At 1-year follow-up, mRS (2.9 vs 5.1, p < 0.001) and the BI (71.3 vs 49.2; p = 0.045) were also better in the crossed leg group. The mortality between the groups differed grossly; only 1 patient died in the crossing group compared to 18 in the noncrossing group (p < 0.001). CONCLUSION: Leg crossing is an easily obtained clinical sign and is independent of additional technical examinations. Leg crossing within the first 15 days after severe stroke indicates a favorable outcome which includes less neurologic deficits, better independence in daily life, and lower rates of death.


Subject(s)
Leg/physiopathology , Stroke/diagnosis , Stroke/physiopathology , Female , Follow-Up Studies , Glasgow Coma Scale , Hospitalization , Humans , Male , Observation , Outcome Assessment, Health Care , Prognosis , Prospective Studies , Retrospective Studies , Severity of Illness Index
4.
J Affect Disord ; 134(1-3): 217-25, 2011 Nov.
Article in English | MEDLINE | ID: mdl-21684012

ABSTRACT

OBJECTIVES: The involvement of an immune process in the pathophysiology of major depression disorder (MDD) was substantiated by studies demonstrating elevated levels of proinflammatory cytokines and prostaglandin E(2) (PGE(2)). Cyclooxygenase-2 (COX-2) inhibitors lead to a reduced production of PGE(2) and have been shown to improve depressive symptoms. We investigated the three immune parameters macrophage migration inhibitory factor (MIF), transforming growth factor-ß (TGF-ß) and soluble CD14 (sCD14) in a randomized, placebo-controlled trial of the COX-2 inhibitor celecoxib as add-on therapy in patients with MDD treated with reboxetine. METHODS: Thirty-two patients with depression and 20 healthy controls participated in the study. The patients were treated with reboxetine and celecoxib or placebo. Immune parameters were measured from serum at baseline, after three and five weeks using ELISA. RESULTS: Celecoxib as add-on strategy resulted in a significant reduction of Hamilton Depression Scale scores compared to placebo. Depressed patients showed significantly elevated MIF (p < 0.001) and reduced TGF-ß (p = 0.006) concentrations at baseline. There was no difference in sCD14-concentrations. There was no difference between the placebo and the celecoxib group and no change over time. LIMITATIONS: Limitations of the study are the relatively small sample size and lack of functional assessment of HPA axis in parallel. CONCLUSIONS: MIF is a promising new candidate in the neuro-immune interplay that may link depressive symptoms, altered immune state and HPA-axis dysregulation. Reduced levels of TGF-ß replicate previous findings and support the importance of this regulatory cytokine in major depressive disorder.


Subject(s)
Cyclooxygenase 2 Inhibitors/therapeutic use , Depressive Disorder, Major/immunology , Intramolecular Oxidoreductases/metabolism , Macrophage Migration-Inhibitory Factors/metabolism , Pyrazoles/therapeutic use , Sulfonamides/therapeutic use , Transforming Growth Factor beta/metabolism , Adult , Aged , Antidepressive Agents/therapeutic use , Celecoxib , Cyclooxygenase 2 , Cyclooxygenase 2 Inhibitors/administration & dosage , Cyclooxygenase 2 Inhibitors/pharmacology , Depression , Depressive Disorder/drug therapy , Depressive Disorder, Major/drug therapy , Depressive Disorder, Major/physiopathology , Drug Therapy, Combination , Enzyme-Linked Immunosorbent Assay , Female , Humans , Male , Middle Aged , Morpholines/therapeutic use , Psychiatric Status Rating Scales , Psychological Tests , Reboxetine , Young Adult
5.
Hum Psychopharmacol ; 25(2): 116-25, 2010 Mar.
Article in English | MEDLINE | ID: mdl-20196179

ABSTRACT

BACKGROUND: To examine influencing variables of neurocognition in patients with schizophrenia and to predict cognition during antipsychotic treatment. METHODS: Data were obtained from patients with an acute episode of schizophrenia participating in two double-blind and one open label trial comparing the effects of different atypical antipsychotics on cognition. In total, 129 patients were enrolled in this analysis. Cognitive function was assessed at admission, week 4 and 8. Efficacy and tolerability were assessed weekly using the Positive and Negative Syndrome Scale (PANSS) and the Simpson Angus Sale (SAS). Patients were treated with aripirazole, olanzapine, quetiapine and risperidone. Regression analysis including mixed effect models was performed. RESULTS: A significant improvement in all cognitive domains was observed from baseline to week 8. Regarding the antipsychotic treatment applied quetiapine seemed to achieve the most favourable cognitive improvement. Negative and depressive symptoms, the patient's age and the concomitant and antipsychotic treatment applied were observed to significantly influence and predict neurocognition. CONCLUSION: The results may indicate that schizophrenia is a static disorder with trait and state dependent cognitive components especially in the memory domains. The influence of negative and depressive symptoms should be considered in daily clinical routine.


Subject(s)
Antipsychotic Agents/therapeutic use , Cognition Disorders/complications , Cognition/drug effects , Neurons/drug effects , Schizophrenia/complications , Schizophrenia/drug therapy , Acute Disease , Adolescent , Adult , Aged , Aging , Antipsychotic Agents/administration & dosage , Antipsychotic Agents/adverse effects , Cognition Disorders/physiopathology , Diagnostic and Statistical Manual of Mental Disorders , Drug Interactions , Humans , Memory/drug effects , Memory Disorders/complications , Memory Disorders/physiopathology , Middle Aged , Schizophrenia/physiopathology , Schizophrenia/therapy , Severity of Illness Index , Time Factors , Young Adult
6.
Pharmacopsychiatry ; 43(2): 50-7, 2010 Mar.
Article in English | MEDLINE | ID: mdl-20336597

ABSTRACT

BACKGROUND: The aim of this study was to assess the cognitive effects of aripiprazole in inpatients with schizophrenia. METHODS: This was an investigator-initiated, open label eight-week trial evaluating 56 inpatients with the DSM-IV diagnosis of schizophrenia. Efficacy was assessed weekly using the Positive and Negative Syndrome Scale (PANSS) and tolerability was assessed each week using the Udvalg for Klinske Undersogelser side effect rating scale (UKU). Cognitive function was assessed at baseline, week 4 and week 8. RESULTS: Aripiprazole showed significant improvement in PANSS total score and all subscores between baseline and endpoint visit. The substance was very well tolerated. Patients improved significantly in verbal memory, reaction time and reaction quality/attention from baseline to week eight. Furthermore, mean z-values of individual cognitive domains summarized in a global cognitive index improved significantly from baseline to week eight. DISCUSSION: Our results suggest that aripiprazole provides a valuable treatment option for patients with schizophrenia.


Subject(s)
Antipsychotic Agents/therapeutic use , Cognition/drug effects , Piperazines/therapeutic use , Quinolones/therapeutic use , Schizophrenia/drug therapy , Adult , Antipsychotic Agents/adverse effects , Aripiprazole , Attention/drug effects , Humans , Inpatients , Memory/drug effects , Neuropsychological Tests , Piperazines/adverse effects , Psychiatric Status Rating Scales , Quinolones/adverse effects , Reaction Time/drug effects , Time Factors , Treatment Outcome
7.
Eur Arch Psychiatry Clin Neurosci ; 256(8): 522-31, 2006 Dec.
Article in English | MEDLINE | ID: mdl-17151834

ABSTRACT

BACKGROUND: Working memory as a part of higher-order executive functions is defined by the parallel storage and processing of information. Recent functional fMRI studies have revealed a functional, interregional disintegration of a neuronal network connecting cortical, subcortical and cerebellar regions in schizophrenic patients (SZ). Cognitive impairment in working memory is a core psychopathological correlate of schizophrenic symptoms. Atypical neuroleptics such as quetiapine have shown good efficacy in treating positive and negative symptoms. The presented study evaluated the impact of a neuroleptic steady state treatment with quetiapine on the altered working memory activation patterns in schizophrenia. METHODS: Patients were examined by fMRI at baseline and after 12 weeks of steady state treatment with quetiapine. Matched healthy controls (HC) underwent baseline examination. In the scanner, stimuli were presented in a 2-back and 0-back condition of a working memory (wm) paradigm, whereby a degraded and a non-degraded version were used each time. Additionally, behavioural responses (reaction time to target stimuli and error ratio) were measured. RESULTS: At baseline, healthy controls revealed increased activity in the frontal lobe, especially in regions of the prefrontal cortex. Compared to HC, SZ showed hypoactivation in the right dorsolateral prefrontal cortex (DLPFC) and the ventrolateral prefrontal cortex (VLPFC) bilaterally for the 2-back condition. In the 2-back degraded condition there was a hypoactivation in both, the right DLPFC and the VLPFC. Additionally, patients showed bilaterally decreased activation in the basalganglia in the 2-back and in the right caudatus in the 2-back degraded condition compared to healthy controls. After treatment with quetiapine, patients activations patterns were increased. The pre-post comparison of the 2-back condition revealed a significant increase of activation in the left VLPFC at a significance level of 0.001 (uncorrected). The 2-back degraded condition led to a significant activation pattern in the lingual gyrus and the right precuneus. In both wm conditions, at baseline there were no differences in reaction time but only a worse performance in SZ. After treatment, behavioural measurement of responses, including reaction time and performance, showed slight improvements in SZ, although these did not reach statistical significance. CONCLUSIONS: The neuronal networks underlying working memory are clearly altered in schizophrenia. After 12 weeks of treatment with quetiapine monotherapy, patients showed significant clinical improvement and revealed increased BOLD activity in the VLPFC during a working memory task, although there was no improvement of cognitive performance.


Subject(s)
Antipsychotic Agents/therapeutic use , Basal Ganglia/drug effects , Cerebellum/drug effects , Cerebral Cortex/drug effects , Dibenzothiazepines/therapeutic use , Image Processing, Computer-Assisted , Imaging, Three-Dimensional , Magnetic Resonance Imaging , Memory, Short-Term/drug effects , Nerve Net/drug effects , Oxygen/blood , Schizophrenia/drug therapy , Schizophrenic Psychology , Adult , Antipsychotic Agents/adverse effects , Basal Ganglia/physiopathology , Cerebellum/physiopathology , Cerebral Cortex/physiopathology , Dibenzothiazepines/adverse effects , Discrimination Learning/drug effects , Discrimination Learning/physiology , Dominance, Cerebral/physiology , Female , Frontal Lobe/drug effects , Frontal Lobe/physiology , Humans , Male , Memory, Short-Term/physiology , Middle Aged , Nerve Net/physiopathology , Pattern Recognition, Visual/drug effects , Pattern Recognition, Visual/physiology , Prefrontal Cortex/drug effects , Prefrontal Cortex/physiology , Quetiapine Fumarate , Reaction Time/drug effects , Reaction Time/physiology , Schizophrenia/physiopathology , Treatment Outcome
8.
Mol Psychiatry ; 11(7): 680-4, 2006 Jul.
Article in English | MEDLINE | ID: mdl-16491133

ABSTRACT

Signs of an inflammatory process, in particular increased pro-inflammatory cytokines and increased levels of prostaglandine E(2) (PGE(2)), have repeatedly been described in major depression (MD). As cyclooxygenase-2 (COX-2) inhibitors inhibit the PGE(2) production and the production of pro-inflammatory cytokines, we performed a therapeutic trial with the COX-2 inhibitor celecoxib. In a prospective, double-blind, add-on study, 40 patients suffering from an acute depressive episode were randomly assigned to either reboxetine and celecoxib or to reboxetine plus placebo. After a wash-out period, 20 patients received 4-10 mg reboxetine plus placebo and 20 received reboxetine plus 400 mg celecoxib for 6 weeks. The treatment effect was calculated by analysis of variance. There were no significant differences between groups in age, sex, duration or severity of disease or psychopathology, or reboxetine dose or plasma levels. Over 6 weeks, both groups of patients showed significant improvement in scores of the Hamilton Depression Scale. However, the celecoxib group showed significantly greater improvement compared to the reboxetine-alone group. Additional treatment with celecoxib has significant positive effects on the therapeutic action of reboxetine with regard to depressive symptomatology. Moreover, the fact that treatment with an anti-inflammatory drug showed beneficial effects on MD indicates that inflammation is related to the pathomechanism of the disorder, although the exact mechanisms remain to become elucidated.


Subject(s)
Antidepressive Agents/therapeutic use , Cyclooxygenase 2 Inhibitors/therapeutic use , Depressive Disorder/drug therapy , Dinoprostone/biosynthesis , Morpholines/therapeutic use , Pyrazoles/therapeutic use , Sulfonamides/therapeutic use , Adrenergic Uptake Inhibitors , Adult , Anti-Anxiety Agents/administration & dosage , Anti-Anxiety Agents/therapeutic use , Antidepressive Agents/administration & dosage , Antidepressive Agents/pharmacology , Celecoxib , Cyclooxygenase 2 Inhibitors/administration & dosage , Cyclooxygenase 2 Inhibitors/pharmacology , Depressive Disorder/physiopathology , Dinoprostone/analysis , Double-Blind Method , Drug Therapy, Combination , Female , Humans , Inflammation/drug therapy , Inflammation/physiopathology , Interleukin-6/biosynthesis , Lorazepam/administration & dosage , Lorazepam/therapeutic use , Male , Middle Aged , Morpholines/administration & dosage , Patient Dropouts , Pilot Projects , Psychological Tests , Pyrazoles/administration & dosage , Pyrazoles/pharmacology , Reboxetine , Serotonin/metabolism , Severity of Illness Index , Sulfonamides/administration & dosage , Sulfonamides/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...